Philips recalled 14 Brilliance iCT SP CT systems on August 13, 2025. The patient support table may descend unexpectedly due to a component misalignment. The recall affects devices distributed worldwide, including the US and 49 other countries.
The patient support table (couch) may descend unexpectedly to the lowermost position due to a component (ball screw) misalignment after a replacement.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Philips North America Llc or your healthcare provider for instructions. Notification method: Letter
The recalled product is the Brilliance iCT SP, Model Number: 728311. These CT systems were distributed globally, including the US, Argentina, Australia, and many European countries. The quantity recalled is 14 units.
The patient support table may descend unexpectedly to its lowest position. This poses a high risk of injury to patients during use.
No specific incidents have been reported yet. The recall is classified as Class II, indicating a high hazard level.
Stop using the device immediately. Contact Philips North America or your healthcare provider for further instructions and follow the recall guidelines.
For more information, visit Philips North America's website or call customer service. Additional details are available at the FDA's recall report link.
Glenmark Pharmaceuticals Inc. recalled 13,824 tubes of Azelaic Acid Gel on September 17, 2025. The recall stems from market complaints regarding a gritty texture. Consumers should stop using the product immediately and contact their healthcare provider.
Skin MD by Dr Monika Kiripolsky recalled its Body Acne Cleanser on September 12, 2025. The recall follows the discovery of elevated benzene levels in the product. This contamination poses a high health risk to consumers in California and Georgia.
Private Label Skin Care recalled its Micronized BPO Gel Cleanser 10% on September 12, 2025. Elevated benzene levels prompted the recall in California and Georgia. Consumers must stop using the product immediately and seek guidance from healthcare providers.